Immuron (IMC.AX) Osake Kurssi

Immuron Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Immuron Ltd in the market include pharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., and GlaxoSmithKline plc. These companies also focus on the development and commercialization of innovative medical treatments and therapies. Immuron Ltd faces competition in the biopharmaceutical sector, where companies strive to deliver groundbreaking products and solutions. It is essential for Immuron Ltd to leverage its unique technology, research capabilities, and collaborations to stay competitive and ensure its continued success in the market.

Immuron Ltd, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in the development and commercialization of oral immunotherapeutics for the treatment and prevention of a range of gut-mediated diseases. Established in 1994, Immuron has a rich history of research and development in the field of immunotherapy. The company focuses on utilizing its proprietary technology platforms to create safe and effective treatments targeting gut-related disorders. With a strong commitment to innovation, Immuron has successfully brought multiple products to market and continues to advance its pipeline. Through strategic partnerships and collaborations, Immuron aims to expand its global presence and improve patient outcomes worldwide.

Immuron Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a phase 2 clinical trial for its flagship product, IMM-124E, which demonstrated promising results in treating nonalcoholic steatohepatitis (NASH). Secondly, Immuron successfully obtained patents for its IMM-529 product, which aids in preventing travelers' diarrhea and helps military personnel. Moreover, the company expanded its market presence through strategic collaborations with top-tier organizations. Immuron also received regulatory approvals, such as from the FDA and TGA, further validating the effectiveness and safety of its products. These milestones highlight Immuron Ltd's commitment to innovation and its mission to improve global healthcare.

Immuron Ltd is primarily present in Australia and the United States.

Immuron Ltd represents a commitment to developing novel immunotherapy solutions for infectious and inflammatory diseases. With a focus on gut health, the company aims to address unmet medical needs through its unique oral immunotherapeutic platform. Immuron actively engages in research and clinical trials to provide safe and effective treatments for conditions caused by microbial imbalances. By harnessing the power of the immune system, Immuron seeks to improve people's lives and contribute to advances in healthcare. The company's dedication to innovation and patient well-being underpins its corporate philosophy, driving its mission to revolutionize the field of immunotherapy.

Nykyisellä valuuttakurssilla Immuron-osake noteerataan hintaan 0,03 EUR (0,04 AUD).

Immuron-osake (IMC.AX) on listattuna 3 pörssissä, muun muassa: ASX (IMC.AX), Frankfurt (ANW.F), München (ANW.MU).

Immuron Ltd is an Australian-based biopharmaceutical company mainly engaged in the research and development of orally administered immunotherapies. The company focuses on combating life-threatening bacterial infections and immune system dysfunctions. Immuron's main business area is the development of IMM-124E, a medical product used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. IMM-124E is a combination of milk antibodies and other active compounds aimed at reducing inflammation, liver cell damage, and fat accumulation in the liver. Immuron is also involved in the development of IMM-529, an orally administered product used for the prevention and treatment of traveler's diarrhea. It contains polyclonal antibodies produced against diarrhea-causing bacteria. The company has also started developing ImmunoN'hancer, another product that can be used for immunosuppression related to inflammatory bowel diseases and immunotherapy for various types of cancer. Immuron is also expanding into the field of animal health, offering a wide range of products including Oralzyme, a supplement to support dental and oral health in dogs and cats, and Travelan, used to prevent traveler's diarrhea in dogs and cats. In conclusion, Immuron is a leading player in immunotherapy and aims to improve patients' lives through its advanced products, innovative research, and strategic partnerships. The company is committed to sustainable development and strives to create products that are beneficial for both patient health and the environment.

liikevaihto Immuron on 7,71 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

voitto Immuron on −3,84 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Immuron:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,39. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Immuron-osakkeen arvostusta.

Immuron:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,69. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Immuron-osakkeen arvostuskennuslukuna.

Immuron:n Eulpool-laatuscore on 4/10.

Immuron:n ISIN on AU000000IMC7. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Immuron:n WKN on A0RDPK. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Immuron:n ticker on IMC.AX. Tämä pörssinoteeraus käytetään Immuron-osakkeiden kauppaan pörssissä.